The partnership could improve the speed, cost and success rate of drug development.
Photo/Thumb have been modified. Courtesy of Victor Moussa - stock.adobe.com.
Last week, Kingdom Capital and the Washington University School of Medicine launched PercayAI, an artificial intelligence (AI) company which aims to help researchers develop new drugs more quickly and successfully.
PercayAI today announced a strategic partnership with Canopy Biosciences to help achieve its mission.
Canopy Biosciences is a multi-omics service provider and will offer PercayAI’s first software product, CompBio, coupled with its RNAseq and NanoString service. The RNAseq assesses the expression of genes and determines the efficacy of single or combination drug studies. NanoString analyzes the expression of up to 800 genes. Samples can be sent in and Canopy Biosciences will return a detailed gene expression report.
CompBio uses AI to provide data in an interactive 3D format for researchers to view all of the information specific to their biologic paradigm. The software could help scientists have a better understanding of the biology behind their research, PercayAI said.
“Through our partnership with Canopy Biosciences, scientists will now have access to a powerful and innovative technological service that will help to improve the speed, cost and success rate of diagnostic and drug development,” said Preston Keller, Ph.D., director and chief commercial officer of PercayAI.
Combining the services of PercayAI and Canopy Biosciences could lead to the rapid identification of non-obvious relationships within complex biological data sets, the companies said.
“Our collaboration with PercayAI will create a powerful union of genomics expertise with cutting-edge analysis solutions to best support scientists in drug development and lead to better patient outcomes,” said Edward Weinstein, Ph.D., CEO of Canopy Biosciences.
Get the best insights in digital health directly to your inbox.